Answers are grounded in this paper and cite their sources.
Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. (Funded by Janssen Research and Development; UNIFI ClinicalTrials.gov number, NCT02407236.).
No takes yet. Share an insight, caveat, or question.
Feagan et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: